Resmetirom

Resmetirom (MGL-3196) is a highly selective and orally active thyroid hormone receptor β (THR-β) agonist with an EC50 value of 0.21 μM. Resmetirom can be used for the study of noncirrhotic nonalcoholic steatohepatitis[1].

Product Specifications

CAS Number

[920509-32-6]

Product Name Alternative

MGL-3196; VIA-3196

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Thyroid Hormone Receptor

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/MGL-3196.html

Purity

99.90

Solubility

DMSO : 75 mg/mL (ultrasonic)

Smiles

N#CC1=NN(C2=CC(Cl)=C(OC(C=C3C(C)C)=NNC3=O)C(Cl)=C2)C(NC1=O)=O

Molecular Formula

C17H12Cl2N6O4

Molecular Weight

435.22

Precautions

H302, H315, H319, H335

References & Citations

[1]Kelly MJ, et al. Discovery of 2-[3,5-dichloro-4- (5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy) phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia. J Med Chem. 2014 May 22;57 (10) :3912-23.